Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The Translational Research Office (TRO) manage a number of devolved funding streams targeting early stage proof-of-concept projects and have extensive knowledge of the UK translational funding landscape. We can help source the most appropriate funding scheme for projects and ensure that the most compelling cases for support are generated. Securing funding enables projects to progress along the translational path, de-risking future investment.

Illustration of financial concepts, including graphs, calculator and percentages

KEY ACTIVITIES

The TRO administrate translational proof-of-concept funding through the Medical and Life Sciences Translation Fund (MLSTF). The fund is open to all University of Oxford researchers and provides consolidated internal proof of concept funding for translational medical and life sciences projects.

The TRO also identify the most appropriate external grant funding source for a project. A few of the translational research funding schemes available to researchers are:

Award

Application deadline(s)

Award volume and duration

Comments

Translational Therapeutics Accelerator (TRxA)

CriticalPathInstitute.png

Call for Pre-proposals deadline: 27th June 2024. 

A pilot Protein-Based Therapeutics (PBT) Request for Proposals: up to $250,000 for up to 1 year.

 

 

TRxA leverages the proficiency of Critical Path Institute in translational and regulatory science to advance the drug development projects by providing academic researchers with funding and guidance for the advancement of novel therapeutics from the lab to clinical trials and, ultimately, commercialization and patient care.

 

MRC Developmental Pathway Funding Scheme (DPFS)

 

MRC logo

 

Stage 1 (Outline): 5th of June 2024

 

Stage 2: By invitation only after shortlisting

Award Volume: There is no limit to the amount of funding you can apply for. You should justify the resources needed in the context of the proposed work.

Duration: There is no limit to the duration of your project. You should justify the timescale of the project in the context of the proposed work.

This scheme aims to drive fundamental discoveries stemming from MRC’s research boards and the wider academic community along the developmental pathway towards patient benefit and or commercialisation

Cancer Research Horizons Seed Fund

Logo for Cancer Research Horizon

Rolling deadline

£50k to £100-£500k, with ability to invest up to £1m on occasion.

Early-stage validation, pre-seed, seed, and follow-on capital available.

Contact: Gillian.Shuttleworth@cancer.org.uk

Cancer Research Horizons Data Innovation Awards

Logo for Cancer Research Horizon

Rolling deadline

<£75k, <12 months

Funding to support cleaning, annotation, curation, linking or storage of CRUK-funded data that has significant commercial potential.

Contact: Gillian.Shuttleworth@cancer.org.uk

Cancer Research Horizons Entrepreneurial Programme

Logo for Cancer Research Horizon

Various (please check website)

£10k to £70k

Training opportunities to learn how to pitch your idea, build a business and attract investment.  Early market discovery, accelerator, and startup funding available.

Contact: Gillian.Shuttleworth@cancer.org.uk

Cancer Research Horizons Project Development Fund

Logo for Cancer Research Horizon

Rolling deadline

<£50K (£50K + applications considered if strong rationale),<12 months

To bridge a gap to get your project to the next stage.

Proposal should have a clearly defined endpoint that is achievable in the short to medium term). CRUK-funding is a prerequisite and proposals must be consistent with Cancer Research Horizon's vision and purpose

Contact: Gillian.Shuttleworth@cancer.org.uk

BBSRC-EPSRC IAAs Highlight OpportunityBBSRC IAA Header

EPSRC Header

 

Highlight applications should be submitted through the EPSRC-BBSRC IAA Highlight by 4pm, 4 June 2024, and will be assessed by an EPSRC-BBSRC IAA panel. Projects should start no later than 1 October 2024.

Projects can be up to twelve months in duration and up to £50-70k in value (or if higher, provide good justification) 

The TRO and MPLS EPSRC IAA have opened a new BBSRC EPSRC Highlight to co-fund translation projects that overlap in EPSRC and BBSRC remit. This highlight will fund interdisciplinary applications that use engineering, physical and computational science research outputs to address challenges in the following areas that are relevant to BBSRC-EPSRC remits.

Up to £150k available to fund 2-3 new translation projects in priority areas of:

  • Engineering Biology
  • Robotics and Agriculture
  • Artificial Intelligence and Agriculture
  • Antimicrobial resistance

The call will support innovative projects that involve:

  • interdisciplinary collaboration, and
  • user engagement, or
  • market validation, or
  • technology development, commercialisation.

Only applications that are interdisciplinary and fit BBSRC-EPSRC remits will be considered for the Highlight call.

Action Medical Research: Research Training Fellowship Action Medical Research Header

 

Opening Date: April 2024

Outline Applications closing date: 2 July 2024 5pm

Decision: February 2025

Award: March 2025

Fellowship, 24-36 months duration

The upper limit of funding for a fellowship is £275,000. 

The Research Training Fellowship (RTF) scheme aims to train research leaders of the future in child health. The fellowship provides the opportunity to undertake a period of research training which will be relevant to applicants’ future careers, developing their skills in research techniques and methodology in subjects relevant to Action’s remit.

Applications are invited from medical graduates, clinicians, bioengineers, research nurses, physiotherapists and allied health professionals who wish to develop a long-term career in academic medicine in the UK in areas relevant to child health.

Further information can be found here

Small molecule High Throughput Screen using AstraZeneca facilities

UKRI header

Opening date: 9 May 2024 9:00am 

Closing date: 4 July 2024 4:00pm 

Project duration is typically 15 months, however projects can be from 12 months (minimum) to a maximum of 18 months.

The maximum award for the program is £270,000

Apply for funding to run a High Throughput Screen using AstraZeneca’s compound library and screening robots. Funding priority in this round will be given to applications related to fibrosis or extracellular matrix targets.

Two funding opportunities a year with new thematic focus each round. Future areas will include:

  • autoimmunity
  • pain
  • motor neuron disease
  • mental health
  • dementias (including Parkinson’s and Huntington’s)
  • women’s health (including related to metabolic disorders)

The funding opportunity remains open to all targets, these will only be funded if there is insufficient demand in the areas specified in the funding opportunity guidance.

For more information visit the website here.

Experimental Medicine Award by Cancer Research UK

 

Preliminary Submission 4th April 2022

 £1–5M
for up to 5 years

The Experimental Medicine Award funds highly ambitious translational research conducted in association with a clinical trial or well-designed clinical study in the field of oncology. Translational research considered within the scheme must be associated with one or more clinical trials or clinical studies within the lifetime of the award, where it can be clearly demonstrated that the findings would directly impact on the conduct of the trial(s)/studies. Associated trial(s)/studies may be funded as part of an Experimental Medicine Award.

ICURe Discover Programme

New Innovate UK brand launched as part of unified UKRI ...

Opening date: 7 June 2024 12:00pm
Closing date: 19 September 2024 5:00pm

8 weeks

8 weeks part-time, online programme helping early-stage research teams to make the first steps into market discovery.

ICURe Explore Programme

New Innovate UK brand launched as part of unified UKRI ...

Opening date: 4 June 2024 12:00pm

 

Closing date: 10 September 2024 5:00pm

£35k

12 weeks

Up to £35k to ‘get out of the lab’ and validate commercially promising ideas in the marketplace, over 12 week period.

BHF Translational Award

BHF logo — Department of Physiology, Anatomy and Genetics (DPAG)

Deadline for outline stage: 13 December 2023 and 19 June 2024

Full-stage applications by invite only.

£750k

3 years

Up to £750k for projects lasting up to three years that address an unmet healthcare need in heart and circulatory disease.

Therapeutic Catalyst - Cancer Research UK

Cancer Research UK - Wikipedia

Open until awarded.

£250k

18 months

Up to £250k for projects lasting up to 18 months. Drug discovery proposals, including, but not limited to:

- Deconvolution and validation of novel targets and pathways with clear therapeutic potential

- Novel therapeutic approaches to validated targets

- Development of platforms, assays and screens to identify novel cancer therapeutics or targets.

The TRO supports developing robust project plans and compelling applications for funding. Our Translational Research Managers can support grant writing activities, provide project management support and advise on long-term translational research strategies.

The TRO works closely with Oxford University Innovation (OUI), the Medical Sciences Business Partnerships Office (BPO) and University of Oxford's Research Services (RS) to ensure appropriate expertise and advice is sought at key stages in project development.